title: Different somatic alterations of the HRPT2 gene in a patient with recurrent sporadic primary hyperparathyroidism carrying an HRPT2 germline mutation.
abstract: Early onset of primary hyperparathyroidism (PHPT) and multiglandular involvement suggest a familial form in which germline mutation of a PHPT-related gene(s) and a somatic event at the same locus can be often demonstrated. We investigated the involvement of multiple endocrine neoplasia type 1 (MEN1) and HRPT2 genes in a 39-year-old man with recurrent PHPT. PHPT was firstly diagnosed at the age of 21 and the patient had two recurrences separated by extended periods of normocalcemia. This unusual history prompted us to investigate other family members and study the MEN1 and HRPT2 genes. An HRPT2 germline missense mutation in exon 3 (R91P) was found in the index case, which was associated with different HRPT2 somatic alterations in each of the three examined parathyroid tumors. These findings are consistent with Knudson's 'two hit' concept of biallelic inactivation of classical tumor suppressor genes. Screening of 15 asymptomatic relatives was negative for the R91P germline mutation. All the three abnormal parathyroid specimens showed cystic features at histology and were negative for parafibromin immunostaining. In one specimen, diffuse parafibromin staining was evident in a rim of normal parathyroid tissue surrounding the adenomatous lesion. Our study shows that different somatic genetic events at the HRPT2 locus are responsible for the asynchronous occurrence of multiple adenomas in a patient carrying an HRPT2 germline mutation. The finding of diffuse parafibromin staining in a rim of normal parathyroid tissue, but not in the contiguous adenomatous lesion, reinforces the concept that loss of parafibromin expression is responsible for the development of parathyroid tumors in this setting.
authors.affiliation: Department of Endocrinology and Metabolism, University of Pise, Pise, Italy. cetani@endoc.med.unipi.it
authors.forename: F
authors.initials: F
authors.lastname: Cetani
authors.forename: E
authors.initials: E
authors.lastname: Pardi
authors.forename: E
authors.initials: E
authors.lastname: Ambrogini
authors.forename: P
authors.initials: P
authors.lastname: Viacava
authors.forename: S
authors.initials: S
authors.lastname: Borsari
authors.forename: M
authors.initials: M
authors.lastname: Lemmi
authors.forename: L
authors.initials: L
authors.lastname: Cianferotti
authors.forename: P
authors.initials: P
authors.lastname: Miccoli
authors.forename: A
authors.initials: A
authors.lastname: Pinchera
authors.forename: A
authors.initials: A
authors.lastname: Arnold
authors.forename: C
authors.initials: C
authors.lastname: Marcocci
mesh_terms: D000328:Adult; D004252:DNA Mutational Analysis; D018095:Germ-Line Mutation; D006801:Humans; D049950:Hyperparathyroidism, Primary / Q000473:pathology*; D019656:Loss of Heterozygosity; D008297:Male; D020125:Mutation, Missense; D010280:Parathyroid Glands / Q000737:chemistry / Q000473:pathology*; D011518:Proto-Oncogene Proteins / Q000235:genetics; D012008:Recurrence; D025521:Tumor Suppressor Proteins / Q000032:analysis / Q000235:genetics*
chemical_list: C454900:CDC73 protein, human; C105373:MEN1 protein, human; D011518:Proto-Oncogene Proteins; D025521:Tumor Suppressor Proteins